• LAST PRICE
    9.8950
  • TODAY'S CHANGE (%)
    Trending Up0.0850 (0.8665%)
  • Bid / Lots
    9.8900/ 14
  • Ask / Lots
    9.9000/ 10
  • Open / Previous Close
    9.7800 / 9.8100
  • Day Range
    Low 9.7000
    High 9.9850
  • 52 Week Range
    Low 9.0200
    High 14.5700
  • Volume
    330,224
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 9.81
TimeVolumeFOLD
09:32 ET180249.7
09:34 ET12309.77
09:36 ET15969.76
09:38 ET4289.76
09:39 ET33929.75
09:41 ET9819.77
09:43 ET45049.83
09:45 ET185819.86
09:48 ET8079.86
09:50 ET99399.81
09:52 ET31969.8
09:54 ET169129.8
09:56 ET16429.8
09:57 ET6819.79
09:59 ET42009.78
10:01 ET26119.78
10:03 ET159639.78
10:06 ET28979.79
10:08 ET16569.805
10:10 ET13259.825
10:12 ET32829.815
10:14 ET59169.835
10:15 ET14009.815
10:17 ET9009.82
10:19 ET23449.845
10:21 ET19629.855
10:24 ET11009.845
10:26 ET12009.855
10:28 ET6649.85
10:30 ET30009.845
10:32 ET24999.87
10:33 ET22709.87
10:35 ET6149.864
10:37 ET6009.865
10:39 ET9009.87
10:42 ET6499.885
10:44 ET12129.89
10:46 ET22779.885
10:48 ET6499.885
10:50 ET12009.865
10:51 ET4009.865
10:53 ET3009.865
10:55 ET8999.87
10:57 ET1009.86
11:00 ET2009.865
11:02 ET1009.865
11:04 ET12519.87
11:06 ET26709.88
11:08 ET9489.885
11:09 ET2009.88
11:11 ET1009.88
11:13 ET8009.875
11:15 ET6009.875
11:18 ET8009.885
11:20 ET12129.88
11:22 ET39009.885
11:24 ET3009.88
11:26 ET41989.895
11:27 ET6269.895
11:29 ET14009.911
11:31 ET12149.915
11:33 ET10269.915
11:36 ET19579.92
11:38 ET30989.925
11:40 ET5469.925
11:42 ET6009.925
11:44 ET4009.925
11:45 ET73639.945
11:47 ET25199.96
11:49 ET12269.97
11:51 ET49069.975
11:54 ET41999.96
11:56 ET11739.97
11:58 ET29489.96
12:00 ET11009.95
12:02 ET14009.935
12:03 ET16009.94
12:05 ET13599.92
12:07 ET19149.95
12:09 ET9009.945
12:12 ET6269.94
12:14 ET21049.93
12:16 ET21869.935
12:18 ET34649.945
12:20 ET15999.93
12:21 ET1009.93
12:23 ET12529.94
12:25 ET3049.93
12:27 ET23489.925
12:30 ET18359.92
12:32 ET14489.915
12:34 ET21219.91
12:36 ET25529.905
12:38 ET7529.905
12:39 ET36429.895
12:41 ET25729.8939
12:43 ET16489.895
12:45 ET9009.89
12:48 ET12009.885
12:50 ET28949.895
12:52 ET13009.91
12:54 ET20049.92
12:56 ET2269.91
12:57 ET18319.905
12:59 ET2269.905
01:01 ET1009.9
01:03 ET8529.905
01:06 ET5009.905
01:08 ET31189.9
01:10 ET10549.89
01:12 ET9139.89
01:14 ET3069.89
01:15 ET10999.884
01:17 ET16459.885
01:19 ET14359.885
01:21 ET4129.88
01:24 ET9009.895
01:26 ET4959.895
01:28 ET25159.895
01:30 ET3019.895
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesFOLD
Amicus Therapeutics Inc
2.9B
-20.1x
---
United StatesDNLI
Denali Therapeutics Inc
3.0B
-21.8x
---
United StatesMOR
MorphoSys AG
2.8B
-5.4x
---
United StatesGMAB
Genmab A/S
16.7B
21.2x
+22.71%
United StatesRARE
Ultragenyx Pharmaceutical Inc
3.8B
-5.0x
---
United StatesTGTX
TG Therapeutics Inc
2.9B
84.4x
---
As of 2024-07-05

Company Information

Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

Contact Information

Headquarters
3675 Market StreetPHILADELPHIA, PA, United States 19104
Phone
215-921-7600
Fax
609-662-2001

Executives

Independent Chairman of the Board
Michael Raab
President, Chief Executive Officer, Director
Bradley Campbell
Chief Financial Officer
Simon Harford
Chief People Officer
David Clark
Chief Legal Office, General Counsel, Company Secretary
Ellen Rosenberg

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.9B
Revenue (TTM)
$423.5M
Shares Outstanding
296.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.71
EPS
$-0.49
Book Value
$0.55
P/E Ratio
-20.1x
Price/Sales (TTM)
6.9
Price/Cash Flow (TTM)
---
Operating Margin
-19.18%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.